Market Overview
The global Human Blood Albumin market was valued at USD 5.82 billion in 2024 and is projected to reach USD 9.24 billion by 2031, exhibiting a CAGR of 7.0% during the forecast period.
Human serum albumin is the most abundant protein in human plasma, constituting approximately 60% of total plasma protein. It serves critical functions including maintaining oncotic pressure, binding and transporting various molecules (including hormones, fatty acids, and metabolites), antioxidant activity, and acid-base balance. The increasing demand for albumin in therapeutic applications such as hypoalbuminemia treatment, burn and shock resuscitation, and its use as an excipient in drug formulations drives market growth.
Market size
USD 5.82 billion in 2024
2032 USD 9.24 billion by 2031
of 7.0%
Liquid Form Albumin
Lyophilized Powder Form Albumin
Liquid Form Albumin dominates the market due to its immediate therapeutic availability and ease of administration in critical care settings, while lyophilized forms offer superior shelf life and stability for long-term storage in medical facilities.
By Application
Hypoalbuminemia Treatment
Liver Disease Management
Critical Care and Trauma
Other Medical Applications
Hypoalbuminemia Treatment represents the largest application segment due to the critical role of albumin in maintaining oncotic pressure and treating protein deficiencies across diverse patient populations, with growing utilization in multi-disciplinary critical care.
https://www.24lifesciences.com
Our Key Players
CSL Behring (Australia)
Grifols S.A. (Spain)
Octapharma AG (Switzerland)
China Biologic Products Inc. (China)
Hualan Biological Engineering Inc. (China)
Kedrion S.p.A. (Italy)
Sanquin Blood Supply Foundation (Netherlands)
https://www.24lifesciences.com
